The survival of PLHIV-1 by the count of CD4 + T lymphocytes remains essential to predict the treatment of opportunistic infections. The aim of the study was to compare the performance of PIMA™® and FACSPresto™® to the conventional equipment of FACSCount™® through CD4 + T cell counting. CD4 + T lymphocytes were tested both on PIMA™® and BD FACSPresto™®. Values were compared to those obtained from FACSCount™®, using Passing Bablok, Bland-Altman and Pollock diagrams. PIMA™® and FACSPresto™® present a good correlation coefficient with the Passing Bablok diagram (y = −0.5982 + 0.9940x; ρc = 0.9969) and (y = 7.2913 + 0.9974x; ρc = 0.9972) respectively. Bland-Altman and Pollock plots show mean biases of 3.7 cells/μL (LOA ranging from −62.7 to 60.1) and 0.5 cells/μL (LOA ranging from −10.7 to 11.6) for PIMA™® and −1.5 cells/μL (LOA ranging from −45.7 to 42.7) and −1.9 cells/μL (LOA ranging from −23.4 to 19.6) for FACSPresto™®. Sensitivity and specificity of PIMA™® and FACSPresto™® vary respectively between 98 to 99% and 96 to 98% at threshold of 350 cells/μL and 98 to 100% at threshold of 500 cells/μL. Both technologies highlight their ability to be used as an alternative to the reference technique.
No takes yet. Share an insight, caveat, or question.
Tchiakpé et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: